NCT06211881View on ClinicalTrials.gov

Chi-GVM Regimen for the Treatment of R/R PTCL

NARecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 25, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Relapsed/Refractory Peripheral T-cell Lymphoma
Interventions
DRUG

Chi-GVM

"Chi-GVM regimen (every 21 days is a treatment cycle):~Chidamide 20 mg orally;gemcitabine 1g/m2, twice a week, intravenous infusion on day 1, vinorelbine 20 mg/m2, infusion on day 1; Mitoxantrone Hydrochloride Liposome12 mg/m2, intravenous infusion on day 1; Chidamide maintenance therapy: 20 mg orally twice a week/28 days/cycle."

Trial Locations (1)

210029

RECRUITING

Hematological Department, People's Hospital of Jiangsu Province, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER